SomaLogic, Inc. (SLGC)

Market Cap	426.92M
Revenue (ttm)	101.39M
Net Income (ttm)	-141.17M
Shares Out	188.07M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	663,726
Open	2.28
Previous Close	2.26
Day's Range	2.24 - 2.32
52-Week Range	1.93 - 3.79
Beta	1.67
Analysts	Strong Buy
Price Target	6.33 (+178.86%)
Earnings Date	Nov 13, 2023

About SLGC

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker ...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2000
• Employees: 451
• Stock Exchange: NASDAQ
• Ticker Symbol: SLGC

Financial Performance

In 2022, SomaLogic's revenue was $97.67 million, an increase of 19.65% compared to the previous year's $81.63 million. Losses were -$109.16 million, 24.7% more than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for SLGC stock is "Strong Buy." The 12-month stock price forecast is $6.33, which is an increase of 178.86% from the latest price.

Price Target

$6.33

(178.86% upside)

Analyst Consensus: Strong Buy